Drug Profile


Alternative Names: BMS 426707-01

Latest Information Update: 21 Dec 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antihyperglycaemics; Oxazoles
  • Mechanism of Action Peroxisome proliferator-activated receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 15 Nov 2006 No development reported - Phase-I/II for Type-2 diabetes mellitus in USA (unspecified route)
  • 23 Jan 2006 Bristol-Myers Squibb and Merck have terminated their collaboration agreement for muraglitazar and peliglitazar, a back-up compound, for Type-2 diabetes
  • 29 Apr 2004 Phase-I/II clinical trials in Type-2 diabetes mellitus in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top